Skip to main content
. 2024 Jul 24;16(7):e65291. doi: 10.7759/cureus.65291

Figure 1. Comparison between autologous vs allogeneic CAR-T cell.

Figure 1

Autologous cells have longer manufacturing processes, higher costs, and limited redosing but exhibit stronger persistence and a lower risk for CRS. Allogeneic cells are a cheaper, more accessible patient treatment option but are less personalized and display shorter persistence, with a higher risk for CRS and GvHD.

CRS, cytokine release syndrome; GvHD, graft-versus-host disease; CAR-T, chimeric antigen receptor T